Generic Name and Formulations:
Hydrocortisone acetate 0.5%, polymyxin B (as sulfate) 10000 Units/g, neomycin (as sulfate) 0.35%; crm.
Indications for CORTISPORIN:
Short-term use in corticosteroid-responsive dermatoses with secondary infection.
Apply sparingly and massage in 2–4 times daily.
Do not use in eyes, external ear canal if eardrum perforated. Tuberculous, fungal, or viral lesions.
Intertrigo, diaper or stasis dermatitis or ulceration, extensive burns (neomycin may be absorbed). Avoid prolonged use or on large areas. Use lowest effective dose. Monitor for HPA axis suppression; avoid abrupt cessation if used for chronic conditions. Discontinue if infection persists or worsens or if superinfection occurs. Occlusion: not recommended. Pregnancy (Cat.C). Nursing mothers.
Steroid + antibiotics.
Local irritation, folliculitis, hypertrichosis, dermatitis, sensitization, ototoxicity, nephrotoxicity (if neomycin is significantly absorbed), HPA axis suppression (esp. in children), epidermal and dermal atrophy (esp. in thin-skinned or occluded areas).
Clinical Pain Advisor Articles
- History of Migraine May Be Associated With Higher Risk for Cochlear Disorders
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Symptom Severity, Sensory Sensitivity May Indicate Pain Centralization in Chronic Overlapping Pain Conditions
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness